
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id><journal-title-group><journal-title>BMC Nephrology</journal-title></journal-title-group><issn pub-type="epub">1471-2369</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25200959</article-id><article-id pub-id-type="pmc">4167507</article-id><article-id pub-id-type="publisher-id">835</article-id><article-id pub-id-type="doi">10.1186/1471-2369-15-147</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Association of serum levels of FGF23 and &#x003b1;-Klotho with glomerular filtration rate and proteinuria among cardiac patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ozeki</surname><given-names>Michishige</given-names></name><address><email>in3105@poh.osaka-med.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Fujita</surname><given-names>Shu-ichi</given-names></name><address><email>in3073@poh.osaka-med.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kizawa</surname><given-names>Shun</given-names></name><address><email>shun19840210@yahoo.co.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Morita</surname><given-names>Hideaki</given-names></name><address><email>in3068@poh.osaka-med.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sohmiya</surname><given-names>Koichi</given-names></name><address><email>in3025@poh.osaka-med.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hoshiga</surname><given-names>Masaaki</given-names></name><address><email>in1026@poh.osaka-med.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ishizaka</surname><given-names>Nobukazu</given-names></name><address><email>ishizaka@poh.osaka-med.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Cardiology, Osaka Medical College, Takatsuki-shi Daigaku-machi 2&#x02013;7, Osaka, 569-8686 Japan </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>15</volume><elocation-id>147</elocation-id><history><date date-type="received"><day>12</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Ozeki et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Expression and/or excretion of fibroblast growth factor-23 (FGF23) and its co-receptor Klotho are altered in patients with end-stage renal disease. The possibility that the FGF23/&#x003b1;-Klotho system mediates the aggravated cardiovascular outcome among patients with chronic kidney disease (CKD) has been suggested. We determined whether FGF23 and &#x003b1;-Klotho concentrations are altered among patients with reduced renal function and proteinuria.</p></sec><sec><title>Methods</title><p>Serum FGF23 and &#x003b1;-Klotho were measured in cardiology patients who were not undergoing chronic hemodialysis. Estimated glomerular filtration rate (eGFR) was correlated negatively with FGF23 and positively with &#x003b1;-Klotho.</p></sec><sec><title>Results</title><p>The correlation between FGF23 and the renal tubular maximum reabsorption rate of phosphate to the GFR (TmP/GFR) was not significant, but that between FGF23 and serum calcium or inorganic phosphate was significant among patients with an estimated GFR of less than 60&#x000a0;mL/min/m<sup>2</sup>. By stepwise multivariate regression analysis, eGFR was selected as significant predictor for FGF23 or &#x003b1;-Klotho among patients with an estimated GFR of less than 60&#x000a0;mL/min/m<sup>2</sup>; however, urine albumin/creatinine ratio was not selected as a predictor for FGF23 or &#x003b1;-Klotho irrespective of the eGFR levels. In patients with eGFR of &#x0003c;60&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup>, UACR was significantly associated with log(FGF23); but, this association did not remain statistically significant in a multivariate model.</p></sec><sec><title>Conclusions</title><p>Among cardiology patients with various stages of CKD, serum concentrations of FGF23 and &#x003b1;-Klotho were associated with renal function, but not with the extent of proteinuria.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Fibroblast growth factor-23</kwd><kwd>Klotho</kwd><kwd>Chronic kidney disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Fibroblast growth factor-23 (FGF23) plays a crucial role in the regulation of calcium-phosphate metabolism by suppressing the renal tubular reabsorption of phosphate via activation of FGFR-1c in the presence of its co-receptor Klotho, which was originally identified as an anti-aging molecule [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Among patients with end-stage renal disease, serum levels of FGF23 increase in response to elevated serum phosphorus, and those of &#x003b1;-Klotho decrease. Among patients with end-stage renal disease, serum levels of FGF23 increase in response to elevated serum phosphorus. In addition, serum &#x003b1;-Klotho decreases with the progression of renal dysfunction [<xref ref-type="bibr" rid="CR4">4</xref>], which may be attributed to the fact that the membrane protein klotho is expressed predominantly in kidney and brain and that renal expression of klotho is decreased in patients with chronic kidney disease (CKD) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. FGF23 is presumed to exert extrarenal manifestations [<xref ref-type="bibr" rid="CR7">7</xref>], including left ventricular hypertrophy and cardiac systolic dysfunction [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Together with the observation that reduced &#x003b1;-Klotho is associated with coronary artery disease [<xref ref-type="bibr" rid="CR10">10</xref>], these findings suggested that modulation of FGF23/&#x003b1;-Klotho may represent one of the crucial factors underlying the cardiac [<xref ref-type="bibr" rid="CR11">11</xref>] and vascular remodeling observed in patients with CKD.</p><p>In our previous analyses, we found that FGF23 is associated with left ventricular hypertrophy and cardiac systolic dysfunction [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. As a result, therapies that, directly or indirectly, lower serum levels of FGF23 and, in reverse, elevate the serum &#x003b1;-Klotho level, might represent a novel target to slow the cardiac remodeling process [<xref ref-type="bibr" rid="CR14">14</xref>]. Before searching for effective therapeutic strategies, however, we should analyze what determines FGF23/&#x003b1;-Klotho levels in cardiology patients; only a little information is available about FGF23/&#x003b1;-Klotho in non-CKD patients [<xref ref-type="bibr" rid="CR15">15</xref>] as compared with patients in cardiology patients undergoing hemodialysis [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>CKD is defined to be present when low glomerular filtration rate (GFR) and/or enhanced urinary protein excretion, both of which conditions has been shown to be associated with cardiac remodeling [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], exists for certain period of time. However, relationship between FGF23/&#x003b1;-Klotho and proteinuria seems to have been less extensively examined thus far, as compared with that between GFR and FGF23/&#x003b1;-Klotho [<xref ref-type="bibr" rid="CR20">20</xref>]. To this end, in the current study, we investigated the association of the extent of proteinuria, as well as eGFR, with circulating levels of &#x003b1;-Klotho and FGF23 among cardiology patients.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study population</title><p>The current retrospective study was approved by the Ethics Committee of Osaka Medical College. Between October 2012 and January 2014, 190 cardiac inpatients were recruited who provided written informed consent and for whom sufficient information regarding the data analysis was available. After excluding five patients undergoing chronic hemodialysis, 185 patients were enrolled in the current study.</p></sec><sec id="Sec4"><title>Laboratory analysis</title><p>Aliquots of serum and plasma were obtained and stored immediately at &#x02212;80 degrees until use. Calcium (Ca), inorganic phosphate, C-reactive protein (CRP), and B-type natriuretic peptide (BNP) were measured by routine laboratory methods. When serum albumin was 4&#x000a0;mg/dL or lower, serum Ca levels were corrected by the formula: Ca&#x02009;+&#x02009;(4&#x02013;[serum albumin]), and reported as corrected Ca (cCa). Serum levels of intact FGF23 were measured using a two-step FGF23 enzyme-linked immunosorbent assay (ELISA) kit (Kainos Laboratories Inc., Tokyo, Japan), and serum levels of soluble &#x003b1;-Klotho were measured using a solid-phase sandwich ELISA kit (Immuno-Biological Laboratories, Gunma, Japan) according to the manufacturer&#x02019;s instructions. The interclass correlation coefficients (ICC) of intra- and inter-operator reliability for &#x003b1;-Klotho were 0.97 and 0.94, respectively, those for FGF23 have been described elsewhere [<xref ref-type="bibr" rid="CR13">13</xref>]. The eGFR was calculated by the following Modification of Diet in Renal Disease equation for Japanese subjects: eGFR&#x02009;=&#x02009;194&#x02009;&#x000d7;&#x02009;(serum creatinine)<sup>-1.094</sup>&#x02009;&#x000d7;&#x02009;(age)<sup>-0.287</sup>
[<xref ref-type="bibr" rid="CR21">21</xref>]. Urinary albumin in spot urine was measured by turbidimetric immunoassay and corrected to the urinary albumin level, and expressed as mg of albumin per 1&#x000a0;g of creatinine (urine albumin creatinine ratio, UACR).</p><p>Fractional excretion of calcium (FEca) was calculated by the formula: FEca&#x02009;=&#x02009;([urine calcium]&#x02009;&#x000d7;&#x02009;[serum creatinine])/([serum calcium]&#x02009;&#x000d7;&#x02009;[urine creatinine]).Tubular fractional reabsorption of phosphorus (TRP) was calculated by the formula: TRP&#x02009;=&#x02009;1-([urine phosphate]&#x02009;&#x000d7;&#x02009;[serum creatinine])/([serum phosphate]&#x02009;&#x000d7;&#x02009;[urine creatinine]); and percent TRP was calculated by multiplying TRP by 100. The tubular maximum reabsorption of phosphorus per glomerular filtration rate (TmP/GFR [mg/dL]) can be calculated by the following equation [<xref ref-type="bibr" rid="CR22">22</xref>]: If TRP is&#x02009;&#x02264;&#x02009;0.86 (86%), then TmP/GFR&#x02009;=&#x02009;TRP&#x02009;&#x000d7;&#x02009;(serum phosphate). If TRP is&#x02009;&#x0003e;&#x02009;0.86 (86%), then TmP/GFR&#x02009;=&#x02009;(0.3&#x02009;&#x000d7;&#x02009;TRP)/(1&#x02013;0.8&#x02009;&#x000d7;&#x02009;TRP)x(serum phosphate) [<xref ref-type="bibr" rid="CR23">23</xref>]. Urine phosphate/creatinine ratio, percent TRP, and TmP/GFR were found to be normally distributed by Kolmogorov-Smirnov test. On the other hand, eGFR, UACR, urine calcium creatinine ratio, and FEca were not normally distributed, and they were log transformed, termed log(eGFR), log(UACR), log(urine Ca/cr), and log(FEca), respectively.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p>Baseline characteristics were assessed with standard descriptive statistics. Data were expressed as either mean&#x02009;&#x000b1;&#x02009;standard deviation or median and interquartile range. For comparisons of differences between groups, analysis of variance (ANOVA) was used for variables with normal distribution, and Kruskal-Wallis test was used when data were not normally distributed. To assess the correlation between two variables, a Pearson&#x02019;s correlation test was used to assess the correlation between two normally distributed variables; for variables that were not normally distributed, a Spearman rank correlation test was used. For multivariate analysis, multivariate linear regression and multivariate logistic regression analyses were used. Data analysis was performed by SPSS statistics version 22.0 (IBM, Armonk, NY). A value of P&#x02009;&#x0003c;&#x02009;0.05 was taken to be statistically significant.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><sec id="Sec7"><title>Patient characteristics</title><p>Among the 185 patients enrolled in the study, 135 were male (73%). More than half of the study subjects were taking ACE inhibitors and/or AT1 receptor blockers (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Of the 185 patients, 44 (24%), 124 (67%), and 17 (9%) had an eGFR (mL/min/1.73&#x000a0;m<sup>2</sup>) of &#x02265;60, between 30 and 60, and&#x02009;&#x0003c;&#x02009;30, respectively. In addition, 135 (73%), 40 (22%), and 10 (5%) patients had a UACR (mg/g&#x02022;cr) of&#x02009;&#x0003c;&#x02009;30 (normoalbuminic range), between 30 and 300 (microalbuminuric range), and&#x02009;&#x02265;&#x02009;300 (macroalbuminuric range), respectively. Serum FGF23 levels between patients who were and were not taking ACE inhibitor and/or angiotensin II receptor blocker did not differ significantly (data not shown). By contrast, &#x003b1;-Klotho levels in patients who were taking ACE inhibitor and/or angiotensin II receptor blocker (median 317, interquartile range 216&#x02013;427&#x000a0;pg/mL, n&#x02009;=&#x02009;96) were significantly lower than those in patients who were not taking either drug (median 397, interquartile range 221&#x02013;520&#x000a0;pg/mL, n&#x02009;=&#x02009;89) (P&#x02009;=&#x02009;0.045, by Mann&#x02013;Whitney analysis).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Demographic characteristics of the study patients</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4">Variables</th><th colspan="3">Variables</th></tr><tr><th colspan="4">Clinical characteristics</th><th>Laboratory measurements</th><th>Median</th><th>(Interquartile range)</th></tr></thead><tbody><tr><td align="center">Age</td><td align="center">68.9</td><td align="center">&#x000b1;</td><td align="center">11.3</td><td align="center">Complete blood cell count</td><td align="center"/><td align="center"/></tr><tr><td align="center">Sex (women/men)</td><td align="center">50</td><td align="center">/</td><td align="center">135</td><td align="center">White blood cell count. &#x000d7;10<sup>3</sup>/mL</td><td align="center">5.9</td><td align="center">(4.9 - 7.0)</td></tr><tr><td align="center">Body mass index, kg/m<sup>2</sup>
</td><td align="center">23.3</td><td align="center">&#x000b1;</td><td align="center">3.1</td><td align="center">Hemoglobin, g/dL</td><td align="center">13.5</td><td align="center">(12.4 - 14.7)</td></tr><tr><td align="center">Systolic blood pressure, mmHg</td><td align="center">128.2</td><td align="center">&#x000b1;</td><td align="center">19.5</td><td align="center">Platelet count. &#x000d7;10<sup>4</sup>/mL</td><td align="center">20.1</td><td align="center">(17.2 - 25.3)</td></tr><tr><td align="center">Cardiovascular disease</td><td/><td/><td/><td align="center">Blood chemistry</td><td/><td/></tr><tr><td align="center">Ischemic heart disease, n (%)</td><td align="center">124</td><td align="center"/><td align="center">(67.0)</td><td align="center">Total protein, g/dL</td><td align="center">6.9</td><td align="center">(6.6 - 7.4)</td></tr><tr><td align="center">Arrhythmia, n (%)</td><td align="center">43</td><td align="center"/><td align="center">(23.2)</td><td align="center">Albumin, g/dL</td><td align="center">4.0</td><td align="center">(3.8 - 4.2)</td></tr><tr><td align="center">Cardiomyopathy, n (%)</td><td align="center">22</td><td align="center"/><td align="center">(11.9)</td><td align="center">Alanine aminotransferase, IU/L</td><td align="center">19</td><td align="center">(14&#x02013;27)</td></tr><tr><td align="center">NYHA class III/IV, n (%)</td><td align="center">16</td><td align="center"/><td align="center">(8.6)</td><td align="center">Blood urea nitrogen, mg/dL</td><td align="center">17</td><td align="center">(14&#x02013;21)</td></tr><tr><td align="center">Aortic aneurysm, n (%)</td><td align="center">10</td><td align="center"/><td align="center">(5.4)</td><td align="center">Serum creatinine, mg/dL</td><td align="center">0.88</td><td align="center">(0.74 - 1.08)</td></tr><tr><td align="center">Peripheral artery disease, n (%)</td><td align="center">19</td><td align="center"/><td align="center">(10.3)</td><td align="center">eGFR. mL/min/1.73&#x000a0;m<sup>2</sup>
</td><td align="center"/><td align="center">49.5&#x02009;&#x000b1;&#x02009;15.0</td></tr><tr><td align="center">Valvular heart disease, n (%)</td><td align="center">7</td><td align="center"/><td align="center">(3.8)</td><td align="center">C-reactive protein, mg/dL</td><td align="center">0.10</td><td align="center">(0.04 - 0.45)</td></tr><tr><td align="center">Smoking status</td><td align="center"/><td align="center"/><td align="center"/><td align="center">B-type natriuretic peptide, pg/mL</td><td align="center">49.4</td><td align="center">(22.3 - 123.4)</td></tr><tr><td align="center">Never, n (%)</td><td align="center">69</td><td align="center"/><td align="center">(37.3)</td><td align="center">Corrected calcium, mg/dL</td><td align="center">9.1</td><td align="center">(8.8 - 9.4)</td></tr><tr><td align="center">Former, n (%)</td><td align="center">89</td><td align="center"/><td align="center">(48.1)</td><td align="center">Inorganic phosphate, mg/dL</td><td align="center"/><td align="center">3.3&#x02009;&#x000b1;&#x02009;0.5</td></tr><tr><td align="center">Current, n (%)</td><td align="center">27</td><td align="center"/><td align="center">(14.6)</td><td align="center">FGF23, pg/mL</td><td align="center">46.9</td><td align="center">(33.7 - 67.8)</td></tr><tr><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x003b1;-Klotho, pg/mL</td><td align="center">343</td><td align="center">(218&#x02013;474)</td></tr><tr><td align="center">Medication</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">ACE inhibitors/ARB, n (%)</td><td align="center">96</td><td align="center"/><td align="center">(51.9)</td><td align="center">Urine chemistry</td><td align="center"/><td align="center"/></tr><tr><td align="center">Beta blockers, n (%)</td><td align="center">72</td><td align="center"/><td align="center">(38.9)</td><td align="center">Albumin, g/dL</td><td align="center">8.7</td><td align="center">(4.5 - 34.0)</td></tr><tr><td align="center">Calcium channel blockers, n (%)</td><td align="center">84</td><td align="center"/><td align="center">(45.4)</td><td align="center">Creatinine, mg/dL</td><td align="center">74.8</td><td align="center">(42.9 - 126.4)</td></tr><tr><td align="center">Aldosterone antagonist, n (%)</td><td align="center">8</td><td align="center"/><td align="center">(4.3)</td><td align="center">Albumin/creatinine ratio, mg/g</td><td align="center">12.9</td><td align="center">(6.6 - 34.4)</td></tr><tr><td align="center">Sulfonylurea, n (%)</td><td align="center">16</td><td align="center"/><td align="center">(8.6)</td><td align="center">Calcium/creatinine ratio, mg/g</td><td align="center">0.07</td><td align="center">(0.04 - 0.12)</td></tr><tr><td align="center">DPP4 inhibitors, n (%)</td><td align="center">28</td><td align="center"/><td align="center">(15.1)</td><td align="center">Phosphate/creatinine ratio, mg/g</td><td align="center"/><td align="center">0.49&#x02009;&#x000b1;&#x02009;0.21</td></tr><tr><td align="center">Insulin, n (%)</td><td align="center">15</td><td align="center"/><td align="center">(8.1)</td><td align="center">Fractional excretion of calcium, %</td><td align="center">0.73</td><td align="center">(0.42 - 1.12)</td></tr><tr><td align="center">Loop, n (%)</td><td align="center">32</td><td align="center"/><td align="center">(17.3)</td><td align="center">TRP, %</td><td align="center"/><td align="center">86.1&#x02009;&#x000b1;&#x02009;6.7</td></tr><tr><td align="center">Thiazide, n (%)</td><td align="center">15</td><td align="center"/><td align="center">(8.1)</td><td align="center">TmP/GFR, mg/dL</td><td align="center">2.9</td><td align="center">(2.5 - 3.5)</td></tr><tr><td align="center">Statin, n (%)</td><td align="center">96</td><td align="center"/><td align="center">(51.9)</td><td align="center"/><td align="center"/><td align="center"/></tr></tbody></table></table-wrap></p><p>When patients were categorized according to their eGFR levels (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), serum levels of FGF23 and &#x003b1;-Klotho, and parameters related to urine excretion of calcium or phosphate, except urine phosphate creatinine ratio, were significantly different across the groups. For example, &#x003b1;-Klotho, percent TRP and FEca showed a graded decrease, and FGF23 showed a graded increase with the progression of CKD stages. Serum concentrations of FGF23 and &#x003b1;-Klotho in patients with grade 4, but not those in patients with grade 3 CKD, differed significantly from those in patients without CKD (Dunnett&#x02019;s post-hoc analysis).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Laboratory data stratified by eGFR values</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">eGFR &#x02265;60&#x000a0;mL/min/m
<sup>2</sup>
</th><th colspan="2">eGFR 30&#x02013;60&#x000a0;mL/min/m
<sup>2</sup>
</th><th colspan="2">eGFR &#x0003c;30&#x000a0;mL/min/m
<sup>2</sup>
</th><th/></tr><tr><th>Variables</th><th colspan="2">(n = 44)</th><th colspan="2">(n = 124)</th><th colspan="2">(n = 17)</th><th>P value</th></tr></thead><tbody><tr><td align="center">eGFR, mL/min/1.73&#x000a0;m<sup>2</sup>
</td><td align="center"/><td align="center">69.2&#x02009;&#x000b1;&#x02009;8.7</td><td align="center"/><td align="center">45.9&#x02009;&#x000b1;&#x02009;8.4</td><td align="center"/><td align="center">25.6&#x02009;&#x000b1;&#x02009;8.4</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="center">Urine albumin creatinine ratio</td><td align="center">10</td><td align="center">(7&#x02013;55)</td><td align="center">13</td><td align="center">(6&#x02013;27)</td><td align="center">75</td><td align="center">(10&#x02013;196)</td><td align="center">0.036</td></tr><tr><td align="center">Serum cCa, mg/dL</td><td align="center">9.1</td><td align="center">(8.8 - 9.5)</td><td align="center">9.1</td><td align="center">(8.7 - 9.3)</td><td align="center">9.1</td><td align="center">(8.7 - 9.3)</td><td align="center">0.508</td></tr><tr><td align="center">Serum inorganic phosphate, mg/dL</td><td align="center">3.40</td><td align="center">(3.10 - 3.70)</td><td align="center">3.30</td><td align="center">(2.90 - 3.70)</td><td align="center">3.30</td><td align="center">(3.00 - 3.65)</td><td align="center">0.546</td></tr><tr><td align="center">Urine calcium creatinine ratio, mg/g</td><td align="center">0.11</td><td align="center">(0.07 - 0.17)</td><td align="center">0.07</td><td align="center">(0.04 - 0.11)</td><td align="center">0.03</td><td align="center">(0.01 - 0.05)</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="center">Fractional excretion of calcium, %</td><td align="center">0.81</td><td align="center">(0.48 - 1.30)</td><td align="center">0.72</td><td align="center">(0.42 - 1.05)</td><td align="center">0.46</td><td align="center">(0.17 - 0.89)</td><td align="center">0.041</td></tr><tr><td align="center">Urine phosphate creatinine ratio, mg/g</td><td align="center"/><td align="center">0.50&#x02009;&#x000b1;&#x02009;0.23</td><td align="center"/><td align="center">0.49&#x02009;&#x000b1;&#x02009;0.20</td><td align="center"/><td align="center">0.39&#x02009;&#x000b1;&#x02009;0.15</td><td align="center">0.149</td></tr><tr><td align="center">TRP, %</td><td align="center"/><td align="center">90.1&#x02009;&#x000b1;&#x02009;4.9</td><td align="center"/><td align="center">85.5&#x02009;&#x000b1;&#x02009;6.2</td><td align="center"/><td align="center">80.2&#x02009;&#x000b1;&#x02009;8.6</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="center">TmP/GFR, mg/dL</td><td align="center">3.3</td><td align="center">(2.8 - 4.2)</td><td align="center">2.8</td><td align="center">(2.5 - 3.4)</td><td align="center">2.6</td><td align="center">(2.2 - 3.2)</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="center">FGF23, pg/mL</td><td align="center">41.2</td><td align="center">(29.4 - 62.3)</td><td align="center">47.0</td><td align="center">(35.3 - 67.9)</td><td align="center">66.4</td><td align="center">(45.6 - 111.3)</td><td align="center">0.009</td></tr><tr><td align="center">&#x003b1;-Klotho, mg/dL</td><td align="center">425</td><td align="center">(254&#x02013;539)</td><td align="center">351</td><td align="center">(224&#x02013;473)</td><td align="center">211</td><td align="center">(163&#x02013;286)</td><td align="center">0.001</td></tr></tbody></table></table-wrap></p><p>Serum levels of FGF23 or &#x003b1;-Klotho, and the urine parameters described above, except TRP, did not differ according to the albuminuric status (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Laboratory data stratified by UACR values</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">UACR &#x0003c;30&#x000a0;mg/g cr</th><th colspan="2">UACR 30&#x02013;300&#x000a0;mg/g cr</th><th colspan="2">UACR &#x02265;300&#x000a0;mg/g cr</th><th/></tr><tr><th>Variables</th><th colspan="2">(n&#x02009;=&#x02009;135)</th><th colspan="2">(n&#x02009;=&#x02009;40)</th><th colspan="2">(n&#x02009;=&#x02009;10)</th><th>P value</th></tr></thead><tbody><tr><td align="center">eGFR, mL/min/1.73&#x000a0;m<sup>2</sup>
</td><td align="center"/><td align="center">51&#x02009;&#x000b1;&#x02009;14</td><td align="center"/><td align="center">48&#x02009;&#x000b1;&#x02009;17</td><td align="center"/><td align="center">39&#x02009;&#x000b1;&#x02009;17</td><td align="center">0.039</td></tr><tr><td align="center">Urine albumin creatinine ratio</td><td align="center">9</td><td align="center">(5&#x02013;15)</td><td align="center">76</td><td align="center">(51&#x02013;154)</td><td align="center">1241</td><td align="center">(719&#x02013;2045)</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="center">Serum cCa, mg/dL</td><td align="center">9.1</td><td align="center">(8.8 - 9.4)</td><td align="center">9.3</td><td align="center">(8.8 - 9.5)</td><td align="center">9.3</td><td align="center">(8.8 - 9.5)</td><td align="center">0.530</td></tr><tr><td align="center">Serum inorganic phosphate, mg/dL</td><td align="center">3.30</td><td align="center">(2.90 - 3.70)</td><td align="center">3.30</td><td align="center">(2.90 - 3.50)</td><td align="center">3.65</td><td align="center">(3.30 - 3.98)</td><td align="center">0.042</td></tr><tr><td align="center">Urine calcium creatinine ratio</td><td align="center">0.07</td><td align="center">(0.04 - 0.12)</td><td align="center">0.07</td><td align="center">(0.03 - 0.15)</td><td align="center">0.07</td><td align="center">(0.02 - 0.10)</td><td align="center">0.789</td></tr><tr><td align="center">Fractional excretion of calcium, %</td><td align="center">0.73</td><td align="center">(0.43 - 1.06)</td><td align="center">0.71</td><td align="center">(0.36 - 1.50)</td><td align="center">0.74</td><td align="center">(0.38 - 1.33)</td><td align="center">0.984</td></tr><tr><td align="center">Urine phosphate creatinine ratio</td><td align="center"/><td align="center">0.47&#x02009;&#x000b1;&#x02009;0.19</td><td align="center"/><td align="center">0.52&#x02009;&#x000b1;&#x02009;0.23</td><td align="center"/><td align="center">0.59&#x02009;&#x000b1;&#x02009;0.25</td><td align="center">0.088</td></tr><tr><td align="center">TRP, %</td><td align="center"/><td align="center">87.2&#x02009;&#x000b1;&#x02009;5.7</td><td align="center"/><td align="center">84.0&#x02009;&#x000b1;&#x02009;8.0</td><td align="center"/><td align="center">80.6&#x02009;&#x000b1;&#x02009;9.6</td><td align="center">0.001</td></tr><tr><td align="center">TmP/GFR, mg/dL</td><td align="center">3.0</td><td align="center">(2.6 - 3.5)</td><td align="center">2.7</td><td align="center">(2.2 - 3.4)</td><td align="center">2.9</td><td align="center">(2.6 - 3.5)</td><td align="center">0.186</td></tr><tr><td align="center">FGF23, pg/mL</td><td align="center">46.8</td><td align="center">(34.3 - 67.0)</td><td align="center">44.1</td><td align="center">(29.9 - 68.5)</td><td align="center">58.3</td><td align="center">(47.0 - 86.3)</td><td align="center">0.330</td></tr><tr><td align="center">&#x003b1;-Klotho, mg/dL</td><td align="center">345</td><td align="center">(223&#x02013;468)</td><td align="center">330</td><td align="center">(200&#x02013;474)</td><td align="center">358</td><td align="center">(218&#x02013;589)</td><td align="center">0.736</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec8"><title>Correlation between serum FGF23/&#x003b1;-Klotho and eGFR/UACR and other calcium phosphate metabolism-related factors</title><p>Log(eGFR) was significantly associated with log(UACR) with a correlation coefficient of &#x02212;0.190 (P&#x02009;=&#x02009;0.009). FGF23 was significantly correlated negatively with log(eGFR) and positively with log(UACR) (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). As we reported before, &#x003b1;-Klotho was not significantly correlated with serum levels of either calcium or phosphate [<xref ref-type="bibr" rid="CR12">12</xref>]; however,FGF23 showed a positive correlation with serum calcium, which differed from our previous observation [<xref ref-type="bibr" rid="CR12">12</xref>]. Among the urine parameters, FGF23 was significantly correlated with parameters related to calcium excretion, including log(urine Ca/cr) or log(FEca), but not with parameters of phosphate excretion, namely, urine phosphate creatinine ratio, percent TRP, or TmP/GFR (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). When patients were divided according to their CKD status, a significant association between FGF23 and calcium and between FGF23 and phosphate was observed exclusively among those with CKD (i.e., GFR&#x02009;&#x0003c;&#x02009;60&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup>). Among the group of patients with CKD, &#x003b1;-Klotho was significantly correlated with parameters related to calcium excretion, but not with those related to phosphate excretion.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Scatter plots and correlation coefficients between FGF23 or &#x003b1;-Klotho, and estimated glomerular filtration rate (eGFR) or urine albumin/creatinine ratio (UACR). A</bold>. Correlation between log(eGFR) and log(FGF23). <bold>B</bold>. Correlation between log(eGFR) and log(&#x003b1;-Klotho). <bold>C</bold>. Correlation between log(UACR) and log(FGF23). <bold>D</bold>. Correlation between log(UACR) and log(&#x003b1;-Klotho). Spearman&#x02019;s correlation analysis was performed.</p></caption><graphic xlink:href="12882_2014_835_Fig1_HTML" id="d30e1620"/></fig></p><table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Correlation between FGF23/&#x003b1;-Klotho and serum and urine calcium/phosphate-related parameters</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">Total study population</th><th colspan="4">eGFR &#x02265;60&#x000a0;mL/min/m
<sup>2</sup>
</th><th colspan="4">eGFR &#x0003c;60&#x000a0;mL/min/m
<sup>2</sup>
</th></tr><tr><th/><th colspan="2">Log (FGF23)</th><th colspan="2">Log (&#x003b1;-Klotho)</th><th colspan="2">Log (FGF23)</th><th colspan="2">Log (&#x003b1;-Klotho)</th><th colspan="2">Log (FGF23)</th><th colspan="2">Log (&#x003b1;-Klotho)</th></tr></thead><tbody><tr><td align="center">Log (FGF23)</td><td align="center">-</td><td align="center"/><td align="center">&#x02212;0.14</td><td align="center">0.064</td><td align="center">-</td><td align="center"/><td align="center">&#x02212;0.23</td><td align="center">0.138</td><td align="center">-</td><td align="center"/><td align="center">&#x02212;0.10</td><td align="center">0.256</td></tr><tr><td align="center">Log (&#x003b1;-Klotho)</td><td align="center">&#x02212;0.14</td><td align="center">0.064</td><td align="center">-</td><td align="center"/><td align="center">&#x02212;0.23</td><td align="center">0.138</td><td align="center">-</td><td align="center"/><td align="center">&#x02212;0.10</td><td align="center">0.256</td><td align="center">-</td><td align="center"/></tr><tr><td align="center">Log (cCa)</td><td align="center">0.22</td><td align="center">0.003</td><td align="center">0.06-</td><td align="center">0.444</td><td align="center">0.13</td><td align="center">0.395</td><td align="center">0.09</td><td align="center">0.553</td><td align="center">0.26</td><td align="center">0.002</td><td align="center">0.05</td><td align="center">0.559</td></tr><tr><td align="center">Inorganic phosphate</td><td align="center">0.23</td><td align="center">0.002</td><td align="center">0.05</td><td align="center">0.509</td><td align="center">0.11</td><td align="center">0.469</td><td align="center">&#x02212;0.25</td><td align="center">0.104</td><td align="center">0.27</td><td align="center">0.001</td><td align="center">&#x02212;0.01</td><td align="center">0.934</td></tr><tr><td align="center">Log (urine Ca/cr)</td><td align="center">&#x02212;0.15</td><td align="center">0.039</td><td align="center">0.22</td><td align="center">0.003</td><td align="center">&#x02212;0.23</td><td align="center">0.134</td><td align="center">&#x02212;0.05</td><td align="center">0.735</td><td align="center">&#x02212;0.09</td><td align="center">0.311</td><td align="center">0.26</td><td align="center">0.002</td></tr><tr><td align="center">Log (FEca)</td><td align="center">&#x02212;0.15</td><td align="center">0.045</td><td align="center">0.15</td><td align="center">0.037</td><td align="center">&#x02212;0.25</td><td align="center">0.106</td><td align="center">&#x02212;0.04</td><td align="center">0.786</td><td align="center">&#x02212;0.10</td><td align="center">0.247</td><td align="center">0.19</td><td align="center">0.021</td></tr><tr><td align="center">Urine phosphate creatinine ratio</td><td align="center">0.07</td><td align="center">0.348</td><td align="center">0.03</td><td align="center">0.728</td><td align="center">&#x02212;0.09</td><td align="center">0.544</td><td align="center">&#x02212;0.13</td><td align="center">0.411</td><td align="center">0.12</td><td align="center">0.153</td><td align="center">0.08</td><td align="center">0.363</td></tr><tr><td align="center">Percent TRP</td><td align="center">&#x02212;0.14</td><td align="center">0.064</td><td align="center">0.11</td><td align="center">0.124</td><td align="center">0.15</td><td align="center">0.331</td><td align="center">0.03</td><td align="center">0.858</td><td align="center">&#x02212;0.14</td><td align="center">0.099</td><td align="center">0.08</td><td align="center">0.331</td></tr><tr><td align="center">Log (TmP/GFR)</td><td align="center">0.07</td><td align="center">0.355</td><td align="center">0.04</td><td align="center">0.634</td><td align="center">0.17</td><td align="center">0.276</td><td align="center">&#x02212;0.13</td><td align="center">0.385</td><td align="center">0.10</td><td align="center">0.247</td><td align="center">0.04</td><td align="center">0.638</td></tr></tbody></table><table-wrap-foot><p>For the correlation between log(FGF23) and log(&#x003b1;-Klotho) and between log(FGF23) or log(&#x003b1;-Klotho) and inorganic phosphate, urine phosphate creatinine ratio, percent TRP, and log(TmP/GFR), Pearson&#x02019;s correlation test was used. Spearman&#x02019;s correlation test was used otherwise.</p></table-wrap-foot></table-wrap></sec><sec id="Sec9"><title>Linear regression analysis</title><p>Next, we performed univariate and multivariate analyses for patients using log(FGF23) or log(&#x003b1;-Klotho) as an independent variable (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). eGFR was associated with both log(FGF23) and log(&#x003b1;-Klotho); and log(cCa) and inorganic phosphate were associated significantly with log(FGF23), but not with log(&#x003b1;-Klotho), consistent with the correlation analysis. Multivariate stepwise regression analysis showed that age, eGFR, log(cCa), and inorganic phosphate were selected as significant predictor for log(FGF23), and only eGFR was selected as a predictor for log(&#x003b1;-Klotho).<table-wrap id="Tab5"><label>Table 5</label><caption><p>
<bold>Linear regression analysis</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Univariate model</th><th colspan="3">Stepwise multivariate model</th></tr><tr><th>Predictors</th><th>Std &#x003b2;</th><th>(95% confidence interval)</th><th>P value</th><th>Std &#x003b2;</th><th>(95% confidence interval)</th><th>P value</th></tr></thead><tbody><tr><td align="center">dependent variable: Log(FGF23)</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Sex (male&#x02009;=&#x02009;1)</td><td align="center">&#x02212;0.02</td><td align="center">(&#x02212;0.17 - 0.12)</td><td align="center">0.741</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Age</td><td align="center">0.21</td><td align="center">(0.07 - 0.35)</td><td align="center">0.004</td><td align="center">0.16</td><td align="center">(0.01 - 0.30)</td><td align="center">0.034</td></tr><tr><td align="center">eGFR</td><td align="center">&#x02212;0.21</td><td align="center">(&#x02212;0.35 - -0.07)</td><td align="center">0.004</td><td align="center">&#x02212;0.16</td><td align="center">(&#x02212;0.34 - -0.02)</td><td align="center">0.027</td></tr><tr><td align="center">Log(UACR)</td><td align="center">0.13</td><td align="center">(&#x02212;0.01 - 0.28)</td><td align="center">0.077</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Log(cCa)</td><td align="center">0.24</td><td align="center">(0.10 - 0.38)</td><td align="center">0.001</td><td align="center">0.21</td><td align="center">(0.07 - 0.35)</td><td align="center">0.003</td></tr><tr><td align="center">Inorganic phosphate</td><td align="center">0.23</td><td align="center">(0.09 - 0.37)</td><td align="center">0.002</td><td align="center">0.19</td><td align="center">(0.05 - 0.33)</td><td align="center">0.007</td></tr><tr><td align="center">Dependent variable: log(&#x003b1;-Klotho)</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Sex (male&#x02009;=&#x02009;1)</td><td align="center">0.00</td><td align="center">(&#x02212;0.14 - 0.15)</td><td align="center">0.955</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Age</td><td align="center">&#x02212;0.14</td><td align="center">(&#x02212;0.28 - 0.01)</td><td align="center">0.064</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">eGFR</td><td align="center">0.24</td><td align="center">(0.10 - 0.39)</td><td align="center">0.001</td><td align="center">0.24</td><td align="center">(0.10 - 0.39)</td><td align="center">0.001</td></tr><tr><td align="center">Log(UACR)</td><td align="center">&#x02212;0.01</td><td align="center">(&#x02212;0.15- 0.14)</td><td align="center">0.931</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Log(cCa)</td><td align="center">&#x02212;0.03</td><td align="center">(&#x02212;0.18 - 0.12)</td><td align="center">0.680</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="char">Inorganic phosphate</td><td align="center">&#x02212;0.05</td><td align="center">(&#x02212;0.19 - 0.10)</td><td align="center">0.509</td><td align="center"/><td align="center"/><td align="center"/></tr></tbody></table></table-wrap></p><p>We also performed a linear regression analysis after dividing the study population according to their CKD status. None of the parameters tested was selected as a significant predictor for either log(FGF23) or log(&#x003b1;-Klotho) among patients in the no CKD group (Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>). By univariate analysis, log(UACR) was found to be associated with log(FGF23) among patients with CKD; however, the association did not remain significant in a stepwise multivariate model.<table-wrap id="Tab6"><label>Table 6</label><caption><p>
<bold>Linear regression analysis among no-CKD and CKD groups</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">eGFR &#x02265;60&#x000a0;mL/min/m
<sup>2</sup>
</th><th colspan="6">eGFR &#x0003c;60&#x000a0;mL/min/m
<sup>2</sup>
</th></tr><tr><th/><th colspan="3">Univariate model</th><th colspan="3">Univariate model</th><th colspan="3">Stepwise multivariate model</th></tr><tr><th>Predictors</th><th>Std &#x003b2;</th><th>(95% confidence interval)</th><th>P value</th><th>Std &#x003b2;</th><th>(95% confidence interval)</th><th>P value</th><th>Std &#x003b2;</th><th>(95% confidence interval)</th><th>P value</th></tr></thead><tbody><tr><td align="center">Dependent varialble: log(FGF23)</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Sex (male&#x02009;=&#x02009;1)</td><td align="center">0.05</td><td align="center">(&#x02212;0.26 - 0.36)</td><td align="center">0.743</td><td align="center">&#x02212;0.10</td><td align="center">(&#x02212;0.27 - 0.06)</td><td align="center">0.227</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Age</td><td align="center">0.08</td><td align="center">(&#x02212;0.23 - 0.39)</td><td align="center">0.589</td><td align="center">0.23</td><td align="center">(0.07-0.39)</td><td align="center">0.006</td><td align="center">0.24</td><td align="center">(0.08 - 0.39)</td><td align="center">0.003</td></tr><tr><td align="center">eGFR</td><td align="center">&#x02212;0.02</td><td align="center">(&#x02212;0.34 - 0.29)</td><td align="center">0.874</td><td align="center">&#x02212;0.19</td><td align="center">(&#x02212;0.35 - -0.02)</td><td align="center">0.025</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Log(UACR)</td><td align="center">&#x02212;0.05</td><td align="center">(&#x02212;0.36 - 0.26)</td><td align="center">0.742</td><td align="center">0.18</td><td align="center">(0.01 - 0.34)</td><td align="center">0.037</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Log(cCa)</td><td align="center">0.22</td><td align="center">(&#x02212;0.08 - 0.52)</td><td align="center">0.150</td><td align="center">0.24</td><td align="center">(0.08 - 0.40)</td><td align="center">0.004</td><td align="center">0.21</td><td align="center">(0.06 - 0.37)</td><td align="center">0.008</td></tr><tr><td align="center">Inorganic phosphate</td><td align="center">0.11</td><td align="center">(&#x02212;0.20 - 0.42)</td><td align="center">0.469</td><td align="center">0.27</td><td align="center">(0.10 - 0.43)</td><td align="center">0.001</td><td align="center">0.21</td><td align="center">(0.05 - 0.37)</td><td align="center">0.011</td></tr><tr><td align="center">Dependent variable: log(&#x003b1;-Klotho)</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Sex (male&#x02009;=&#x02009;1)</td><td align="center">0.11</td><td align="center">(&#x02212;0.20 - 0.42)</td><td align="center">0.474</td><td align="center">0.02</td><td align="center">(&#x02212;0.14 - 0.19)</td><td align="center">0.794</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Age</td><td align="center">&#x02212;0.17</td><td align="center">(&#x02212;0.48 - 0.14)</td><td align="center">0.269</td><td align="center">&#x02212;0.09</td><td align="center">(&#x02212;0.15 - 0.19)</td><td align="center">0.794</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">eGFR</td><td align="center">0.09</td><td align="center">(&#x02212;0.22 - 0.40)</td><td align="center">0.564</td><td align="center">0.24</td><td align="center">(0.08 - 0.40)</td><td align="center">0.004</td><td align="center">0.24</td><td align="center">(0.08 - 0.40)</td><td align="center">0.004</td></tr><tr><td align="center">Log(UACR)</td><td align="center">&#x02212;0.09</td><td align="center">(&#x02212;0.40 - 0.22)</td><td align="center">0.551</td><td align="center">0.02</td><td align="center">(&#x02212;0.15 - 0.18)</td><td align="center">0.844</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Log(cCa)</td><td align="center">0.00</td><td align="center">(&#x02212;0.31 - 0.31)</td><td align="center">0.995</td><td align="center">&#x02212;0.03</td><td align="center">(&#x02212;0.20 - 0.13)</td><td align="center">0.685</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Inorganic phosphate</td><td align="center">&#x02212;0.19</td><td align="center">(0.52 - 0.13)</td><td align="center">0.237</td><td align="center">&#x02212;0.01</td><td align="center">(&#x02212;0.17 - 0.16)</td><td align="center">0.934</td><td align="center"/><td align="center"/><td align="center"/></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec10" sec-type="discussion"><title>Discussion</title><p>It was found that serum FGF23 was correlated with both eGFR and UACR in a univariate model (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). When the study patients were categorized by their eGFR values, FGF23 showed a graded increase and &#x003b1;-Klotho showed a graded decrease according to the progression of CKD stages (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). On the other hand, such an association was not apparent when the patients were divided according to the albuminuric status (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). In the multivariate regression model, eGFR was selected as, respectively, a significant negative and positive predictor for serum FGF23 and &#x003b1;-Klotho; in contrast, UACR was not selected as a predictor (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).</p><p>It is increasingly recognized that both a low glomerular filtration rate and increased urinary protein excretion are associated with an adverse cardiac or cardiovascular outcome [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Both low eGFR [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] and proteinuria [<xref ref-type="bibr" rid="CR26">26</xref>] have been shown to be associated with cardiac remodeling. On the other hand, as compared with the relationship between eGFR and FGF23/&#x003b1;-Klotho, information seems to be limited regarding the relationship association between proteinuria (or albuminuria) and FGF23/&#x003b1;-Klotho. Lundberg et al. demonstrated that, among patients with IgA nephropathy, FGF23 was significantly correlated with both albuminuria and eGFR, although they did not explore this relationship in a multivariate model [<xref ref-type="bibr" rid="CR27">27</xref>]. When we analyzed the patients who did and did not have eGFR values in the CKD range (i.e., &#x0003c; 60&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup>), FGF23 levels were found to be related to eGFR in those with CKD, but not in those without (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). These findings were consistent with the notion that factors other than eGFR, proteinuria, or inorganic phosphate may have a role in modulating FGF23 levels [<xref ref-type="bibr" rid="CR15">15</xref>]. In our previous study, we showed that, even among patients without CKD, higher serum FGF23 tended to be associated with lower systolic function [<xref ref-type="bibr" rid="CR12">12</xref>]; therefore, such factors, if present at all, should be pursued among cardiology patients in future studies.</p><p>Klotho is expressed predominantly in the kidney and, to the less extent, in the brain. As described above, previous studies have shown that, in parallel with the reduction of glomerular filtration rate, renal expression of klotho is decreased [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], which may explain the lower circulating &#x003b1;-Klotho level among in patients with low eGFR [<xref ref-type="bibr" rid="CR4">4</xref>]. These findings are consistent with the finding in the current study, that serum &#x003b1;-Klotho was decreased especially in the patients in the higher CKD grades. On the other hand, &#x003b1;-Klotho was not associated with the extent of proteinuria, regardless of the presence or absence of a decline in renal function in the current study.</p><p>Several experimental [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>] and human studies [<xref ref-type="bibr" rid="CR30">30</xref>] suggested the possible relationship between the extent of proteinuria and renal klotho expression. The observation that drug intervention that can potently decrease proteinuria increases renal Klotho expression or circulating &#x003b1;-Klotho levels in aging-related renal injury [<xref ref-type="bibr" rid="CR31">31</xref>] or diabetic nephropathy [<xref ref-type="bibr" rid="CR32">32</xref>] may further suggest the possible interaction between Klotho expression or secretion is decreased and proteinuria. On the other hand, Kim et al. reported that eGFR, but not proteinuria, was found to be associated with &#x003b1;-Klotho level using a statistical model that include both eGFR and proteinuria [<xref ref-type="bibr" rid="CR4">4</xref>]. Karalliedde et al. showed that, although angiotensin II receptor blockage increased soluble Klotho, the extent of albuminuria was not associated with soluble Klotho, in diabetic subjects [<xref ref-type="bibr" rid="CR33">33</xref>]. Similarly, Lim et al. reported that reduction of proteinuria by angiotensin II receptor blocker, but not by angiotensin converting enzyme (ACE) inhibitor resulted in an increase in the circulating &#x003b1;-Klotho in diabetic patients. These finding may collectively suggest that extent of proteinuria by itself is not be a determinant of circulating &#x003b1;-Klotho, although how angiotensin II receptor blocker cause an increase in &#x003b1;-klotho expression and secretion is unknown [<xref ref-type="bibr" rid="CR32">32</xref>]. Our data also indicate that serum &#x003b1;-Klotho is related to renal function, but not to the extent of proteinuria, at least among cardiology patients.</p><p>We also examined the relationship between FGF23/&#x003b1;-Klotho and urine excretion of calcium and phosphate (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). It was rather unexpected that FGF23 levels were not significantly correlated with TmP/GFR. FGF23 regulates urinary phosphate excretion, as well as production of vitamin D and parathyroid hormone. FGF23 was shown to be positively associated with TmP/GFR in healthy subjects [<xref ref-type="bibr" rid="CR34">34</xref>], and, in addition, phosphaturic activities of FGF23 have also been convincingly demonstrated in the genetically engineered animal models [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>] and in a patient with high FGF23 levels due to tumor-induced osteomalacia [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p>On the other hand, Komo et al. reported in an analysis of data from patients referred to their hospital for osteoporosis treatment, that serum FGF23 was not correlated with inorganic phosphate, corrected calcium, or TmP/GFR [<xref ref-type="bibr" rid="CR38">38</xref>]. They speculated that association between FGF23 and TmP/GFR may be weaker in the absence of severe renal dysfunction. Consistent with their notion findings, association between FGF23 and TmP/GFR was significant, albeit borderline, among patients with CKD in the current study population (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Of note, it is known that resistance to the elevated FGF23 may occur in some diseased conditions, such as autosomal dominant polycystic kidney disease [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Although the precise mechanism of this resistance remains unclear, decreased renal Klotho expression is presumed to play a role. Whether FGF23 resistance is present among patients with certain cardiac or vascular disorder should be investigated in future studies.</p><p>The current study has some limitations. First, ACE inhibitors and/or angiotensin II receptor blockers were prescribed for a substantial proportion of the study subjects, and patients who were taking these medications had lower serum &#x003b1;-Klotho than those who were not. Because this was not a randomized interventional study, however, we are not able to draw conclusions about whether or not these medications increase or decrease serum &#x003b1;-Klotho. Second, we excluded patients who were undergoing chronic hemodialysis; therefore, the relationship between FGF23/&#x003b1;-Klotho and renal function may be underestimated [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec11" sec-type="conclusions"><title>Conclusions</title><p>Among cardiology patients, eGFR, but not the extent of proteinuria, was independently associated with serum levels of FGF23 and &#x003b1;-Klotho. In addition to clarifying the prognostic importance of these molecules for the prediction of outcome [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], the investigation of factors that are and are not related to FGF23/&#x003b1;-Klotho should be continued in order to discover how to modulate the FGF23/&#x003b1;-Klotho axis for the therapeutic purpose.</p></sec></body><back><fn-group><fn><p><bold>Competing interest</bold></p><p>The authors declare that they have no competing interest.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>MO performed the statistical analysis and database creation. SF performed the statistical analysis. SK, HM and KS made substantial contributions to acquisition and interpretation of data. MH involved in drafting the manuscript for important intellectual content. NI participated in the design of the study. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported in part by Grants in Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ADHR Consortium</collab></person-group><article-title>Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23</article-title><source>Nat Genet</source><year>2000</year><volume>26</volume><issue>3</issue><fpage>345</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1038/81664</pub-id><pub-id pub-id-type="pmid">11062477</pub-id></element-citation></ref><ref id="CR2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>T</given-names></name><name><surname>Mizutani</surname><given-names>S</given-names></name><name><surname>Muto</surname><given-names>T</given-names></name><name><surname>Yoneya</surname><given-names>T</given-names></name><name><surname>Hino</surname><given-names>R</given-names></name><name><surname>Takeda</surname><given-names>S</given-names></name><name><surname>Takeuchi</surname><given-names>Y</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Fukumoto</surname><given-names>S</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name></person-group><article-title>Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><issue>11</issue><fpage>6500</fpage><lpage>6505</lpage><pub-id pub-id-type="doi">10.1073/pnas.101545198</pub-id><pub-id pub-id-type="pmid">11344269</pub-id></element-citation></ref><ref id="CR3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuro-o</surname><given-names>M</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Aizawa</surname><given-names>H</given-names></name><name><surname>Kawaguchi</surname><given-names>H</given-names></name><name><surname>Suga</surname><given-names>T</given-names></name><name><surname>Utsugi</surname><given-names>T</given-names></name><name><surname>Ohyama</surname><given-names>Y</given-names></name><name><surname>Kurabayashi</surname><given-names>M</given-names></name><name><surname>Kaname</surname><given-names>T</given-names></name><name><surname>Kume</surname><given-names>E</given-names></name><name><surname>Iwasaki</surname><given-names>H</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Shiraki-Iida</surname><given-names>T</given-names></name><name><surname>Nishikawa</surname><given-names>S</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name><name><surname>Nabeshima</surname><given-names>YI</given-names></name><name><surname>Kuro-o</surname><given-names>M</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Aizawa</surname><given-names>H</given-names></name><name><surname>Kawaguchi</surname><given-names>H</given-names></name><name><surname>Suga</surname><given-names>T</given-names></name><name><surname>Utsugi</surname><given-names>T</given-names></name><name><surname>Ohyama</surname><given-names>Y</given-names></name><name><surname>Kurabayashi</surname><given-names>M</given-names></name><name><surname>Kaname</surname><given-names>T</given-names></name><name><surname>Kume</surname><given-names>E</given-names></name><name><surname>Iwasaki</surname><given-names>H</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Shiraki-Iida</surname><given-names>T</given-names></name><name><surname>Nishikawa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mutation of the mouse klotho gene leads to a syndrome resembling ageing</article-title><source>Nature</source><year>1997</year><volume>390</volume><issue>6655</issue><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/36285</pub-id><pub-id pub-id-type="pmid">9363890</pub-id></element-citation></ref><ref id="CR4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Nam</surname><given-names>BY</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Kang</surname><given-names>MW</given-names></name><name><surname>Han</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Shin</surname><given-names>DH</given-names></name><name><surname>Doh</surname><given-names>FM</given-names></name><name><surname>Koo</surname><given-names>HM</given-names></name><name><surname>Ko</surname><given-names>KI</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Oh</surname><given-names>HJ</given-names></name><name><surname>Yoo</surname><given-names>TH</given-names></name><name><surname>Kang</surname><given-names>SW</given-names></name><name><surname>Han</surname><given-names>DS</given-names></name><name><surname>Han</surname><given-names>SH</given-names></name></person-group><article-title>Circulating alpha-klotho levels in CKD and relationship to progression</article-title><source>Am J Kidney Dis</source><year>2013</year><volume>61</volume><issue>6</issue><fpage>899</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2013.01.024</pub-id><pub-id pub-id-type="pmid">23540260</pub-id></element-citation></ref><ref id="CR5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>N</given-names></name><name><surname>Fujimori</surname><given-names>T</given-names></name><name><surname>Nishiguchi</surname><given-names>S</given-names></name><name><surname>Tamori</surname><given-names>A</given-names></name><name><surname>Shiomi</surname><given-names>S</given-names></name><name><surname>Nakatani</surname><given-names>T</given-names></name><name><surname>Sugimura</surname><given-names>K</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Kinoshita</surname><given-names>S</given-names></name><name><surname>Kuroki</surname><given-names>T</given-names></name><name><surname>Nabeshima</surname><given-names>Y</given-names></name></person-group><article-title>Severely reduced production of klotho in human chronic renal failure kidney</article-title><source>Biochem Biophys Res Commun</source><year>2001</year><volume>280</volume><issue>4</issue><fpage>1015</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.4226</pub-id><pub-id pub-id-type="pmid">11162628</pub-id></element-citation></ref><ref id="CR6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakan</surname><given-names>H</given-names></name><name><surname>Nakatani</surname><given-names>K</given-names></name><name><surname>Asai</surname><given-names>O</given-names></name><name><surname>Imura</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Yoshimoto</surname><given-names>S</given-names></name><name><surname>Iwamoto</surname><given-names>N</given-names></name><name><surname>Kurumatani</surname><given-names>N</given-names></name><name><surname>Iwano</surname><given-names>M</given-names></name><name><surname>Nabeshima</surname><given-names>Y</given-names></name><name><surname>Konishi</surname><given-names>N</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name></person-group><article-title>Reduced renal alpha-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>e86301</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0086301</pub-id><pub-id pub-id-type="pmid">24466013</pub-id></element-citation></ref><ref id="CR7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>David</surname><given-names>V</given-names></name><name><surname>Quarles</surname><given-names>LD</given-names></name></person-group><article-title>Regulation and function of the FGF23/klotho endocrine pathways</article-title><source>Physiol Rev</source><year>2012</year><volume>92</volume><issue>1</issue><fpage>131</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1152/physrev.00002.2011</pub-id><pub-id pub-id-type="pmid">22298654</pub-id></element-citation></ref><ref id="CR8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guti&#x000e9;rrez</surname><given-names>OM</given-names></name><name><surname>Januzzi</surname><given-names>JL</given-names></name><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Laliberte</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Collerone</surname><given-names>G</given-names></name><name><surname>Sarwar</surname><given-names>A</given-names></name><name><surname>Hoffmann</surname><given-names>U</given-names></name><name><surname>Coglianese</surname><given-names>E</given-names></name><name><surname>Christenson</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>TJ</given-names></name><name><surname>de Filippi</surname><given-names>C</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name></person-group><article-title>Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>19</issue><fpage>2545</fpage><lpage>2552</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.844506</pub-id><pub-id pub-id-type="pmid">19414634</pub-id></element-citation></ref><ref id="CR9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>C</given-names></name><name><surname>Amaral</surname><given-names>AP</given-names></name><name><surname>Oskouei</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>MC</given-names></name><name><surname>Sloan</surname><given-names>A</given-names></name><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>OM</given-names></name><name><surname>Aguillon-Prada</surname><given-names>R</given-names></name><name><surname>Lincoln</surname><given-names>J</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name><name><surname>Mundel</surname><given-names>P</given-names></name><name><surname>Morales</surname><given-names>A</given-names></name><name><surname>Scialla</surname><given-names>J</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Soliman</surname><given-names>EZ</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Rosas</surname><given-names>SE</given-names></name><name><surname>Nessel</surname><given-names>L</given-names></name><name><surname>Townsend</surname><given-names>RR</given-names></name><name><surname>Feldman</surname><given-names>HI</given-names></name><name><surname>St John Sutton</surname><given-names>M</given-names></name><name><surname>Ojo</surname><given-names>A</given-names></name><name><surname>Gadegbeku</surname><given-names>C</given-names></name><name><surname>Di Marco</surname><given-names>GS</given-names></name><name><surname>Reuter</surname><given-names>S</given-names></name><name><surname>Kentrup</surname><given-names>D</given-names></name><name><surname>Tiemann</surname><given-names>K</given-names></name><name><surname>Brand</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>JA</given-names></name><etal/></person-group><article-title>FGF23 induces left ventricular hypertrophy</article-title><source>J Clin Invest</source><year>2011</year><volume>121</volume><issue>11</issue><fpage>4393</fpage><lpage>4408</lpage><pub-id pub-id-type="doi">10.1172/JCI46122</pub-id><pub-id pub-id-type="pmid">21985788</pub-id></element-citation></ref><ref id="CR10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro-Gonzalez</surname><given-names>JF</given-names></name><name><surname>Donate-Correa</surname><given-names>J</given-names></name><name><surname>Muros De Fuentes</surname><given-names>M</given-names></name><name><surname>Perez-Hernandez</surname><given-names>H</given-names></name><name><surname>Martinez-Sanz</surname><given-names>R</given-names></name><name><surname>Mora-Fernandez</surname><given-names>C</given-names></name></person-group><article-title>Reduced Klotho is associated with the presence and severity of coronary artery disease</article-title><source>Heart</source><year>2014</year><volume>100</volume><issue>1</issue><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2013-304746</pub-id><pub-id pub-id-type="pmid">24165855</pub-id></element-citation></ref><ref id="CR11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Mishra</surname><given-names>RK</given-names></name><name><surname>Keane</surname><given-names>M</given-names></name><name><surname>Rosas</surname><given-names>SE</given-names></name><name><surname>Dries</surname><given-names>D</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>A</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Shlipak</surname><given-names>MG</given-names></name><collab>Chronic Renal Insufficiency Cohort (CRIC) Study Group</collab></person-group><article-title>Associations between kidney function and subclinical cardiac abnormalities in CKD</article-title><source>J Am Soc Nephrol</source><year>2012</year><volume>23</volume><issue>10</issue><fpage>1725</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1681/ASN.2012020145</pub-id><pub-id pub-id-type="pmid">22935481</pub-id></element-citation></ref><ref id="CR12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Fujita</surname><given-names>S</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Sohmiya</surname><given-names>K</given-names></name><name><surname>Hoshiga</surname><given-names>M</given-names></name><name><surname>Ishizaka</surname><given-names>N</given-names></name></person-group><article-title>Association between circulating fibroblast growth factor 23, alpha-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>9</issue><fpage>e73184</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0073184</pub-id><pub-id pub-id-type="pmid">24039882</pub-id></element-citation></ref><ref id="CR13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Sohmiya</surname><given-names>K</given-names></name><name><surname>Hoshiga</surname><given-names>M</given-names></name><name><surname>Ishizaka</surname><given-names>N</given-names></name></person-group><article-title>Serum uric Acid is associated with left ventricular hypertrophy independent of serum parathyroid hormone in male cardiac patients</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>12</issue><fpage>e82735</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0082735</pub-id><pub-id pub-id-type="pmid">24340056</pub-id></element-citation></ref><ref id="CR14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>M</given-names></name></person-group><article-title>Update on fibroblast growth factor 23 in chronic kidney disease</article-title><source>Kidney Int</source><year>2012</year><volume>82</volume><issue>7</issue><fpage>737</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1038/ki.2012.176</pub-id><pub-id pub-id-type="pmid">22622492</pub-id></element-citation></ref><ref id="CR15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>TJ</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Indridason</surname><given-names>OS</given-names></name><name><surname>Quarles</surname><given-names>LD</given-names></name></person-group><article-title>Serum FGF23 levels in normal and disordered phosphorus homeostasis</article-title><source>J Bone Miner Res</source><year>2003</year><volume>18</volume><issue>7</issue><fpage>1227</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2003.18.7.1227</pub-id><pub-id pub-id-type="pmid">12854832</pub-id></element-citation></ref><ref id="CR16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urena Torres</surname><given-names>P</given-names></name><name><surname>Friedlander</surname><given-names>G</given-names></name><name><surname>De Vernejoul</surname><given-names>MC</given-names></name><name><surname>Silve</surname><given-names>C</given-names></name><name><surname>Prie</surname><given-names>D</given-names></name></person-group><article-title>Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients</article-title><source>Kidney Int</source><year>2008</year><volume>73</volume><issue>1</issue><fpage>102</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002622</pub-id><pub-id pub-id-type="pmid">17943081</pub-id></element-citation></ref><ref id="CR17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>K</given-names></name><name><surname>Imura</surname><given-names>A</given-names></name><name><surname>Ohkido</surname><given-names>I</given-names></name><name><surname>Maruyama</surname><given-names>Y</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Urae</surname><given-names>J</given-names></name><name><surname>Sekino</surname><given-names>H</given-names></name><name><surname>Nabeshima</surname><given-names>Y</given-names></name><name><surname>Hosoya</surname><given-names>T</given-names></name></person-group><article-title>Serum soluble alpha-klotho in hemodialysis patients</article-title><source>Clin Nephrol</source><year>2012</year><volume>77</volume><issue>5</issue><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.5414/CN107204</pub-id><pub-id pub-id-type="pmid">22551879</pub-id></element-citation></ref><ref id="CR18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>J</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>St John Sutton</surname><given-names>M</given-names></name><name><surname>Dixit</surname><given-names>S</given-names></name><name><surname>Gerstenfeld</surname><given-names>EP</given-names></name><name><surname>Ghio</surname><given-names>S</given-names></name><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>Shlipak</surname><given-names>MG</given-names></name><name><surname>Deo</surname><given-names>R</given-names></name></person-group><article-title>Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study</article-title><source>Eur J Heart Fail</source><year>2012</year><volume>14</volume><issue>12</issue><fpage>1420</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hfs135</pub-id><pub-id pub-id-type="pmid">22956574</pub-id></element-citation></ref><ref id="CR19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmieri</surname><given-names>V</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Roman</surname><given-names>MJ</given-names></name><name><surname>Liu</surname><given-names>JE</given-names></name><name><surname>Best</surname><given-names>LG</given-names></name><name><surname>Bella</surname><given-names>JN</given-names></name><name><surname>Robbins</surname><given-names>DC</given-names></name><name><surname>Howard</surname><given-names>BV</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name></person-group><article-title>Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><issue>10</issue><fpage>2764</fpage><lpage>2769</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.10.2764</pub-id><pub-id pub-id-type="pmid">14514577</pub-id></element-citation></ref><ref id="CR20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Morgenthaler</surname><given-names>NG</given-names></name><name><surname>Wong</surname><given-names>MD</given-names></name><name><surname>Tavintharan</surname><given-names>S</given-names></name><name><surname>Sum</surname><given-names>CF</given-names></name><name><surname>Lim</surname><given-names>SC</given-names></name></person-group><article-title>Association of plasma soluble alpha-klotho with pro-endothelin-1 in patients with type 2 diabetes</article-title><source>Atherosclerosis</source><year>2014</year><volume>233</volume><issue>2</issue><fpage>415</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.01.024</pub-id><pub-id pub-id-type="pmid">24530772</pub-id></element-citation></ref><ref id="CR21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>S</given-names></name><name><surname>Imai</surname><given-names>E</given-names></name><name><surname>Horio</surname><given-names>M</given-names></name><name><surname>Yasuda</surname><given-names>Y</given-names></name><name><surname>Tomita</surname><given-names>K</given-names></name><name><surname>Nitta</surname><given-names>K</given-names></name><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Tomino</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Hishida</surname><given-names>A</given-names></name></person-group><article-title>Revised equations for estimated GFR from serum creatinine in Japan</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>53</volume><issue>6</issue><fpage>982</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2008.12.034</pub-id><pub-id pub-id-type="pmid">19339088</pub-id></element-citation></ref><ref id="CR22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>AP</given-names></name><name><surname>Glen</surname><given-names>AC</given-names></name></person-group><article-title>Tests of phosphate reabsorption</article-title><source>Lancet</source><year>1973</year><volume>2</volume><issue>7821</issue><fpage>158</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(73)93112-7</pub-id><pub-id pub-id-type="pmid">4124087</pub-id></element-citation></ref><ref id="CR23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>WH</given-names></name><name><surname>Molinolo</surname><given-names>AA</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Collins</surname><given-names>MT</given-names></name></person-group><article-title>Tumor-induced osteomalacia</article-title><source>Endocr Relat Cancer</source><year>2011</year><volume>18</volume><issue>3</issue><fpage>R53</fpage><lpage>R77</lpage><pub-id pub-id-type="doi">10.1530/ERC-11-0006</pub-id><pub-id pub-id-type="pmid">21490240</pub-id></element-citation></ref><ref id="CR24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>McCulloch</surname><given-names>CE</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name></person-group><article-title>Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><issue>13</issue><fpage>1296</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa041031</pub-id><pub-id pub-id-type="pmid">15385656</pub-id></element-citation></ref><ref id="CR25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waheed</surname><given-names>S</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>Sang</surname><given-names>Y</given-names></name><name><surname>Hoogeveen</surname><given-names>R</given-names></name><name><surname>Ballantyne</surname><given-names>C</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Astor</surname><given-names>BC</given-names></name></person-group><article-title>Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study</article-title><source>Am J Kidney Dis</source><year>2012</year><volume>60</volume><issue>2</issue><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2012.03.011</pub-id><pub-id pub-id-type="pmid">22537422</pub-id></element-citation></ref><ref id="CR26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQuarrie</surname><given-names>EP</given-names></name><name><surname>Patel</surname><given-names>RK</given-names></name><name><surname>Mark</surname><given-names>PB</given-names></name><name><surname>Delles</surname><given-names>C</given-names></name><name><surname>Connell</surname><given-names>J</given-names></name><name><surname>Dargie</surname><given-names>HJ</given-names></name><name><surname>Steedman</surname><given-names>T</given-names></name><name><surname>Jardine</surname><given-names>AG</given-names></name></person-group><article-title>Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease</article-title><source>Nephrol Dial Transplant</source><year>2011</year><volume>26</volume><issue>3</issue><fpage>933</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfq418</pub-id><pub-id pub-id-type="pmid">20624770</pub-id></element-citation></ref><ref id="CR27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>S</given-names></name><name><surname>Qureshi</surname><given-names>AR</given-names></name><name><surname>Olivecrona</surname><given-names>S</given-names></name><name><surname>Gunnarsson</surname><given-names>I</given-names></name><name><surname>Jacobson</surname><given-names>SH</given-names></name><name><surname>Larsson</surname><given-names>TE</given-names></name></person-group><article-title>FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy</article-title><source>Clin J Am Soc Nephrol</source><year>2012</year><volume>7</volume><issue>5</issue><fpage>727</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.2215/CJN.10331011</pub-id><pub-id pub-id-type="pmid">22383747</pub-id></element-citation></ref><ref id="CR28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitani</surname><given-names>H</given-names></name><name><surname>Ishizaka</surname><given-names>N</given-names></name><name><surname>Aizawa</surname><given-names>T</given-names></name><name><surname>Ohno</surname><given-names>M</given-names></name><name><surname>Usui</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Amaki</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>I</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Nangaku</surname><given-names>M</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Nagai</surname><given-names>R</given-names></name></person-group><article-title>In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage</article-title><source>Hypertension</source><year>2002</year><volume>39</volume><issue>4</issue><fpage>838</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000013734.33441.EA</pub-id><pub-id pub-id-type="pmid">11967236</pub-id></element-citation></ref><ref id="CR29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanchi</surname><given-names>C</given-names></name><name><surname>Locatelli</surname><given-names>M</given-names></name><name><surname>Benigni</surname><given-names>A</given-names></name><name><surname>Corna</surname><given-names>D</given-names></name><name><surname>Tomasoni</surname><given-names>S</given-names></name><name><surname>Rottoli</surname><given-names>D</given-names></name><name><surname>Gaspari</surname><given-names>F</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name><name><surname>Zoja</surname><given-names>C</given-names></name></person-group><article-title>Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>8</issue><fpage>e70775</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0070775</pub-id><pub-id pub-id-type="pmid">23967103</pub-id></element-citation></ref><ref id="CR30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kacso</surname><given-names>IM</given-names></name><name><surname>Bondor</surname><given-names>CI</given-names></name><name><surname>Kacso</surname><given-names>G</given-names></name></person-group><article-title>Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A</article-title><source>Clin Biochem</source><year>2012</year><volume>45</volume><issue>16&#x02013;17</issue><fpage>1415</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2012.07.098</pub-id><pub-id pub-id-type="pmid">22836100</pub-id></element-citation></ref><ref id="CR31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HC</given-names></name><name><surname>Deleuze</surname><given-names>S</given-names></name><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Potthoff</surname><given-names>SA</given-names></name><name><surname>Ma</surname><given-names>LJ</given-names></name><name><surname>Fogo</surname><given-names>AB</given-names></name></person-group><article-title>The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury</article-title><source>J Am Soc Nephrol</source><year>2009</year><volume>20</volume><issue>11</issue><fpage>2380</fpage><lpage>2388</lpage><pub-id pub-id-type="doi">10.1681/ASN.2008111138</pub-id><pub-id pub-id-type="pmid">19797472</pub-id></element-citation></ref><ref id="CR32"><label>32</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>SC</given-names></name><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Subramaniam</surname><given-names>T</given-names></name><name><surname>Sum</surname><given-names>CF</given-names></name></person-group><article-title>Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients</article-title><source>J Renin Angiotensin Aldosterone Syst</source><year>2013</year></element-citation></ref><ref id="CR33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karalliedde</surname><given-names>J</given-names></name><name><surname>Maltese</surname><given-names>G</given-names></name><name><surname>Hill</surname><given-names>B</given-names></name><name><surname>Viberti</surname><given-names>G</given-names></name><name><surname>Gnudi</surname><given-names>L</given-names></name></person-group><article-title>Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria</article-title><source>Clin J Am Soc Nephrol</source><year>2013</year><volume>8</volume><issue>11</issue><fpage>1899</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.2215/CJN.02700313</pub-id><pub-id pub-id-type="pmid">23929932</pub-id></element-citation></ref><ref id="CR34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gkentzi</surname><given-names>D</given-names></name><name><surname>Efthymiadou</surname><given-names>A</given-names></name><name><surname>Kritikou</surname><given-names>D</given-names></name><name><surname>Chrysis</surname><given-names>D</given-names></name></person-group><article-title>Fibroblast growth factor 23 and Klotho serum levels in healthy children</article-title><source>Bone</source><year>2014</year><volume>66C</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2014.05.012</pub-id><pub-id pub-id-type="pmid">24880094</pub-id></element-citation></ref><ref id="CR35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Goltzman</surname><given-names>D</given-names></name><name><surname>Karaplis</surname><given-names>AC</given-names></name></person-group><article-title>Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders</article-title><source>Endocrinology</source><year>2004</year><volume>145</volume><issue>11</issue><fpage>5269</fpage><lpage>5279</lpage><pub-id pub-id-type="doi">10.1210/en.2004-0233</pub-id><pub-id pub-id-type="pmid">15284207</pub-id></element-citation></ref><ref id="CR36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>T</given-names></name><name><surname>Urakawa</surname><given-names>I</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Hino</surname><given-names>R</given-names></name><name><surname>Yoneya</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>Y</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Fukumoto</surname><given-names>S</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name></person-group><article-title>FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa</article-title><source>Biochem Biophys Res Commun</source><year>2004</year><volume>314</volume><issue>2</issue><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2003.12.102</pub-id><pub-id pub-id-type="pmid">14733920</pub-id></element-citation></ref><ref id="CR37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogura</surname><given-names>E</given-names></name><name><surname>Kageyama</surname><given-names>K</given-names></name><name><surname>Fukumoto</surname><given-names>S</given-names></name><name><surname>Yagihashi</surname><given-names>N</given-names></name><name><surname>Fukuda</surname><given-names>Y</given-names></name><name><surname>Kikuchi</surname><given-names>T</given-names></name><name><surname>Masuda</surname><given-names>M</given-names></name><name><surname>Suda</surname><given-names>T</given-names></name></person-group><article-title>Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23</article-title><source>Intern Med</source><year>2008</year><volume>47</volume><issue>7</issue><fpage>637</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.47.0761</pub-id><pub-id pub-id-type="pmid">18379151</pub-id></element-citation></ref><ref id="CR38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komo</surname><given-names>T</given-names></name></person-group><article-title>Relation between serum FGF-23 and phosphate or bone metabolism in adults</article-title><source>J Osaka City Med Association</source><year>2007</year><volume>56</volume><fpage>35</fpage><lpage>41</lpage></element-citation></ref><ref id="CR39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavik</surname><given-names>I</given-names></name><name><surname>Jaeger</surname><given-names>P</given-names></name><name><surname>Ebner</surname><given-names>L</given-names></name><name><surname>Poster</surname><given-names>D</given-names></name><name><surname>Krauer</surname><given-names>F</given-names></name><name><surname>Kistler</surname><given-names>AD</given-names></name><name><surname>Rentsch</surname><given-names>K</given-names></name><name><surname>Andreisek</surname><given-names>G</given-names></name><name><surname>Wagner</surname><given-names>CA</given-names></name><name><surname>Devuyst</surname><given-names>O</given-names></name><name><surname>W&#x000fc;thrich</surname><given-names>RP</given-names></name><name><surname>Schmid</surname><given-names>C</given-names></name><name><surname>Serra</surname><given-names>AL</given-names></name></person-group><article-title>Soluble klotho and autosomal dominant polycystic kidney disease</article-title><source>Clin J Am Soc Nephrol</source><year>2012</year><volume>7</volume><issue>2</issue><fpage>248</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.2215/CJN.09020911</pub-id><pub-id pub-id-type="pmid">22193235</pub-id></element-citation></ref><ref id="CR40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spichtig</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Mohebbi</surname><given-names>N</given-names></name><name><surname>Pavik</surname><given-names>I</given-names></name><name><surname>Petzold</surname><given-names>K</given-names></name><name><surname>Stange</surname><given-names>G</given-names></name><name><surname>Saleh</surname><given-names>L</given-names></name><name><surname>Edenhofer</surname><given-names>I</given-names></name><name><surname>Segerer</surname><given-names>S</given-names></name><name><surname>Biber</surname><given-names>J</given-names></name><name><surname>Jaeger</surname><given-names>P</given-names></name><name><surname>Serra</surname><given-names>AL</given-names></name><name><surname>Wagner</surname><given-names>CA</given-names></name></person-group><article-title>Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease</article-title><source>Kidney Int</source><year>2014</year><volume>85</volume><issue>6</issue><fpage>1340</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1038/ki.2013.526</pub-id><pub-id pub-id-type="pmid">24402093</pub-id></element-citation></ref><ref id="CR41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scialla</surname><given-names>JJ</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>AH</given-names></name><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Ojo</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Nessel</surname><given-names>L</given-names></name><name><surname>Hamano</surname><given-names>T</given-names></name><name><surname>Grunwald</surname><given-names>JE</given-names></name><name><surname>Raj</surname><given-names>DS</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Lash</surname><given-names>JP</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Kusek</surname><given-names>JW</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><collab>Chronic Renal Insufficiency Cohort (CRIC) Study Investigators</collab></person-group><article-title>Fibroblast growth factor-23 and cardiovascular events in CKD</article-title><source>J Am Soc Nephrol</source><year>2014</year><volume>25</volume><issue>2</issue><fpage>349</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1681/ASN.2013050465</pub-id><pub-id pub-id-type="pmid">24158986</pub-id></element-citation></ref><ref id="CR42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seiler</surname><given-names>S</given-names></name><name><surname>Rogacev</surname><given-names>KS</given-names></name><name><surname>Roth</surname><given-names>HJ</given-names></name><name><surname>Shafein</surname><given-names>P</given-names></name><name><surname>Emrich</surname><given-names>I</given-names></name><name><surname>Neuhaus</surname><given-names>S</given-names></name><name><surname>Floege</surname><given-names>J</given-names></name><name><surname>Fliser</surname><given-names>D</given-names></name><name><surname>Heine</surname><given-names>GH</given-names></name></person-group><article-title>Associations of FGF-23 and sKlotho with Cardiovascular Outcomes among Patients with CKD Stages 2&#x02013;4</article-title><source>Clin J Am Soc Nephrol</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>1049</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.2215/CJN.07870713</pub-id><pub-id pub-id-type="pmid">24677555</pub-id></element-citation></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR43"><mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here: <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2369/15/147/prepub">http://www.biomedcentral.com/1471-2369/15/147/prepub</ext-link></mixed-citation></ref></ref-list></ref-list></back></article>